Business, energy, technology, markets and global industry news from Business News Today

U.S. Food and Drug Administration

PharmaDeviceNews U.S. Food and Drug Administration
Pharma & Biotech

Papillary NMIBC could become the next commercial test for ImmunityBio’s ANKTIVA franchise

ANKTIVA already has an NMIBC foothold. The harder test is whether FDA reviewers accept extrapolation into papillary-only disease.

Read More
Pharma & Biotech

Bayer’s asundexian FDA priority review puts Factor XIa inhibition closer to a real stroke prevention test

Bayer needs a new cardiovascular growth engine. Asundexian’s FDA priority review now tests whether Factor XIa can move from promise to practice.

Read More
Representative image: Clinicians reviewing lung cancer imaging and genomic test results, reflecting Bayer’s HYRNUO FDA Priority Review and the growing role of precision oncology in HER2-mutated non-small cell lung cancer treatment.
Pharma & Biotech

Why Bayer’s HYRNUO first-line FDA review could reshape HER2-mutated NSCLC treatment sequencing

Bayer has FDA momentum in HER2-mutated lung cancer. The harder test is whether HYRNUO can move earlier without stronger survival data.

Read More
Representative image: A surgical team prepares a preserved donor heart in a high-tech transplant setting, reflecting the clinical and regulatory stakes behind United Therapeutics Corporation’s FDA-cleared UHeart xenotransplantation trial for end-stage heart failure.
Pharma & Biotech

Can United Therapeutics turn pig-heart xenotransplantation into a regulated clinical pathway?

A pig-heart trial is no longer just a scientific leap. United Therapeutics now faces the harder test of safety, scale, and regulation.

Read More
HistoSonics seeks FDA kidney tumor authorization as Edison platform expands
Medical Devices & Diagnostics

HistoSonics is taking histotripsy beyond liver tumors. Kidney cancer care may be the next credibility test.

HistoSonics has liver clearance. Kidney tumors are the harder test, where non-invasive ambition must meet regulatory and clinical proof.

Read More
Representative image: A generic inhaler device in a clinical research setting, illustrating Transpire Bio’s FDA-accepted ANDA filing for a proposed generic high-strength Trelegy Ellipta alternative for asthma and COPD treatment.
Pharma & Biotech

What Transpire Bio’s Trelegy ANDA reveals about the next wave of inhaler competition

Trelegy is a blockbuster, but complex inhaler generics are closing in. Transpire Bio’s FDA filing could test GSK’s respiratory moat.

Read More
Representative image: Aurie’s FDA De Novo grant for a reusable no-touch intermittent catheter system highlights a potential shift in urology care, as reusable catheter technology challenges the long-standing dominance of single-use urinary catheters in chronic care settings.
Medical Devices & Diagnostics

Did Aurie just crack the one-use catheter problem hospitals avoided for decades?

Single-use catheters finally face a regulated reuse challenge. Aurie’s FDA De Novo win could shift urology device economics.

Read More
Representative image of a clinician reviewing oncology imaging and molecular testing data, reflecting how BIZENGRI’s FDA approval could advance targeted treatment for NRG1 fusion-positive cholangiocarcinoma.
Pharma & Biotech

Why Partner Therapeutics’ BIZENGRI approval matters beyond cholangiocarcinoma

Rare cancer biology is becoming commercially actionable. BIZENGRI’s FDA approval puts NRG1 fusion testing under sharper scrutiny.

Read More
Representative image: Vistagen’s fasedienol Phase 3 trial highlights the growing search for rapid, as-needed nasal spray treatments for social anxiety disorder, especially in high-pressure public speaking and performance settings.
Pharma & Biotech

Why PALISADE-4 is a high-stakes test for Vistagen’s nose-to-brain anxiety drug strategy

Social anxiety needs faster options. Vistagen’s fasedienol now faces the Phase 3 test that could make or break its nasal-spray thesis.

Read More
Representative image: Advanced liver cancer imaging and RNA-based oncology research illustrate Rznomics Inc.’s FDA RMAT designation for RZ-001 in hepatocellular carcinoma, highlighting the growing role of RNA editing in next-generation cancer therapy.
Pharma & Biotech

FDA RMAT status puts Rznomics’ RNA editing platform under a brighter clinical spotlight

RNA editing just gained a liver cancer spotlight. Rznomics must now prove RZ-001 can turn early response signals into durable clinical value.

Read More